<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-19452" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Biochemistry, Cholecystokinin</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Okonkwo</surname>
            <given-names>Oluchukwu</given-names>
          </name>
          <aff>Brooklyn Hospital Center</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Zezoff</surname>
            <given-names>David</given-names>
          </name>
          <aff>Western University</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Adeyinka</surname>
            <given-names>Adebayo</given-names>
          </name>
          <aff>The Brooklyn Hospital Center</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Oluchukwu Okonkwo declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>David Zezoff declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Adebayo Adeyinka declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>1</day>
          <month>5</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-19452.s1" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>Cholecystokinin (CCK) is a peptide hormone linked&#x000a0;to the gastrointestinal (GI) system. The receptors&#x000a0;are&#x000a0;expressed in the central nervous system<xref ref-type="bibr" rid="article-19452.r1">[1]</xref>&#x000a0;specifically in the hippocampus, cerebral cortex, and striatum <xref ref-type="bibr" rid="article-19452.r2">[2]</xref>. It is present in the nucleus of tractus solitarius and area postrema of the lower portion of the brain stem. CCK is tissue-specific and developmentally regulated. The expression of CCK-endocrine producing cells is biphasic, declines just before birth and increases immediately after birth. Levels of CCK-producing neurons in the brain are low at birth but steadily increase into adulthood. Low levels of CCK are clear in the thyroid C cells, adrenal medulla, bronchial mucosa, pituitary corticotrophs, and spermatogenic cells. CCK-1 and 2 are part of class 1 G-protein-coupled receptor family. CCK1R are found in the gallbladder smooth muscles, chief and D cells of gastric mucosa, pancreatic acinar cells, and selected areas of central and peripheral nervous systems while CCK2R/GR are identified in the stomach (in the parietal, chief, and ECL cell of gastric mucosa), human pancreas and central nervous system (CNS).<xref ref-type="bibr" rid="article-19452.r2">[2]</xref></p>
      </sec>
      <sec id="article-19452.s2" sec-type="Cellular Level&#x0000d;&#x0000a;">
        <title>Cellular Level
</title>
        <p>In peripheral neurons such as those found in the intestinal mucosa, they express CCK in I-cells. Food intake, pituitary adenylate cyclase-activating polypeptide (PACAP), and glucocorticoids play a role in regulating&#x000a0;CCK expression. Estrogen, dopamine, and injury situations activate&#x000a0;CCK-mRNA&#x000a0;in neuronal cells. Activation of transcription factors of these signaling pathways is unknown. Receptors in the CNS are G protein-coupled; CCK-2 receptor subtype&#x000a0;(formerly known as CCK-B) are&#x000a0;found mainly in the brain, and CCK-1 receptor subtype (formerly known as CCK-A) found mainly peripherally, for example, in the pancreas. Adenylyl cyclase is activated inducing a rise in intracellular cyclic adenosine 3', 5'-monophosphate (cAMP) and the activation of protein kinase A (PKA).&#x000a0;They associate this rise in cAMP with CCK-receptor-mediated pathway with high concentrations of CCK. cAMP-dependent protein kinase activity is CCK concentration dependent.&#x000a0;PKA activity peaks rapidly and maintains a high level of activity at high doses of CCK.<xref ref-type="bibr" rid="article-19452.r3">[3]</xref>&#x000a0;CCK receptors found on pancreatic acinar cells have two types of affinity to CCK which elicits different responses. At low concentrations, it stimulates zymogen secretion while at high concentrations CCK inhibits stimulation and secretion of intracellular zymogen proteolysis.<xref ref-type="bibr" rid="article-19452.r3">[3]</xref> Binding sites of CCK-1 and CCK-2 receptors have different affinities for various CCK neuropeptide fragments. CCK-A binding has a higher affinity for sulfated, intermediate, neuropeptide CCK-8 than CCK-4; therefore, most of its action is peripheral. CCK-2R has a high affinity for all CCK &#x000a0;fragments with a higher affinity for CCK-4, alluding to the fact that most of CCK action is on the brain. Stimulation of neuronal pathways containing CCK can amount to a panic-like reaction in humans. Panic attacks could arise from the activation of CCK. CCK antagonists can provide anxiolytic properties via their action on CCK-2 receptors.<xref ref-type="bibr" rid="article-19452.r4">[4]</xref></p>
      </sec>
      <sec id="article-19452.s3" sec-type="Molecular Level&#x0000d;&#x0000a;">
        <title>Molecular Level
</title>
        <p>The specific affinity of membrane receptors on target cells determines the action of CCK and gastrin. CCK-1 and 2 are part of the class 1 G-protein-coupled receptor family. It is made up of seven transmembrane domains connected by intracellular and extracellular loops with an extracellular N-terminal and intracellular C-terminal tails. They divide these receptors into subtypes based on their affinity to CCK or gastrin. The CCK-1 receptor has an affinity 500-times higher for CCK than gastrin. The CCK2 receptor has the same affinity for CCK as it does for gastrin. CCK-1 receptor also has a very high affinity for sulfated CCK than non-sulfated CCK while CCK-2 receptor cannot differentiate between the 2. One of the extracellular loops of CCK-2 receptor contains 5 amino acids paramount to gastrin sensitivity. Loss of His207 from CCK-2 receptor leads to a loss of CCK binding. His207 is also found in the CCK-1 receptor binding site, and an exchange in this region for another amino acid and the Asp region of CCK leads to a loss or gain of affinity. Therefore, the binding sites of CCK-1 and CCK-2 receptors share some homologous regions and the Asp of CCK further demarcates the binding site of the CCK-2 receptor.<xref ref-type="bibr" rid="article-19452.r2">[2]</xref></p>
      </sec>
      <sec id="article-19452.s4" sec-type="Function">
        <title>Function</title>
        <p>
<bold>Roles</bold>
</p>
        <p>
<bold>
<italic toggle="yes">In the Intestine</italic>
</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Mediates digestion by regulating the release of pancreatic exocrine enzymes which plays a role in the digestion of fats, proteins, and carbohydrates</p>
          </list-item>
          <list-item>
            <p>Causes contraction and relaxation of the gallbladder via the sphincter of Oddi in response to food; CCK regulates the release of bile acid to aid in further fat digestion in the small intestine</p>
          </list-item>
          <list-item>
            <p>Regulates overall GI movement, in other words, gut motility<xref ref-type="bibr" rid="article-19452.r5">[5]</xref></p>
          </list-item>
          <list-item>
            <p><xref ref-type="bibr" rid="article-19452.r5">[5]</xref>Regulates gastric emptying: It inhibits gastric emptying to regulate the flow of chyme into the duodenum<xref ref-type="bibr" rid="article-19452.r6">[6]</xref></p>
          </list-item>
          <list-item>
            <p><xref ref-type="bibr" rid="article-19452.r6">[6]</xref>Inhibits gastric acid secretion after a meal by regulating gastrin production via somatostatin<xref ref-type="bibr" rid="article-19452.r7">[7]</xref></p>
          </list-item>
          <list-item>
            <p><xref ref-type="bibr" rid="article-19452.r7">[7]</xref>It enhances the release of leptin which inhibits basal&#x000a0;gastric H+ secretion after a meal. In the intestine, it promotes further absorption of proteins.<xref ref-type="bibr" rid="article-19452.r8">[8]</xref></p>
          </list-item>
          <list-item>
            <p><xref ref-type="bibr" rid="article-19452.r8">[8]</xref>Stimulation of cell growth</p>
          </list-item>
          <list-item>
            <p>Energy production</p>
          </list-item>
          <list-item>
            <p>Gene expression</p>
          </list-item>
          <list-item>
            <p>Protein synthesis</p>
          </list-item>
        </list>
        <p>
<italic toggle="yes">In the Brain</italic>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Regulates feeding behavior: Leptin acts on the brain to inhibit food intake resulting in satiety<xref ref-type="bibr" rid="article-19452.r8">[8]</xref></p>
          </list-item>
          <list-item>
            <p><xref ref-type="bibr" rid="article-19452.r8">[8]</xref>Managing anxiety</p>
          </list-item>
          <list-item>
            <p>Pain perception</p>
          </list-item>
          <list-item>
            <p>Memory</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-19452.s5" sec-type="Mechanism">
        <title>Mechanism</title>
        <p>Fatty acids and proteins stimulate the release of CCK via a direct action on the I-cells. GPR40 is a G-protein-coupled receptor expressed on I-cells that responds&#x000a0;to long-chain fatty acids. Discharge of vagal efferent neurons is stimulated by the action of CCK on CCK-1 receptors and increase intracellular calcium. They find these neurons in both the stomach and small intestines, and CCK initially activates the afferent fibers in the small intestine via a paracrine mechanism. This inhibits the excitatory vagal efferent pathway to the distal stomach. Gastric vagal afferents are stimulated in response to the hormonal effect coupled with the inhibitory vagal efferent pathway to the proximal stomach.<xref ref-type="bibr" rid="article-19452.r9">[9]</xref>&#x000a0;Due to the mechanism mentioned above, CCK can inhibit gastric emptying by relaxing the proximal portion of the stomach, which increases tension in the pyloric sphincter. At high levels of CCK can increase the effect of how fast gastric emptying occurs, and it does this by increasing the excitatory effect it has on both the small and large intestine, which leads to movement in the bowels or by improving the tension of the pyloric sphincter.<xref ref-type="bibr" rid="article-19452.r5">[5]</xref>&#x000a0;Therefore, the reflex control of gastric emptying is regulated by CCK action on vasovagal reflexes and the hormonal activation of a variety of pathways that are coupled to vagal efferent pathways controlling gastric motility.</p>
      </sec>
      <sec id="article-19452.s6" sec-type="Testing">
        <title>Testing</title>
        <p>Gallbladder dysfunction is defined as an abnormally low gallbladder ejection fraction (GBEF).<xref ref-type="bibr" rid="article-19452.r10">[10]</xref>&#x000a0;Gallbladder disease can manifest as bladder dyskinesia, chronic acalculous cholecystitis, biliary dyskinesia, and functional gallbladder disorder, among others. Cholecystokinin scintigraphy (CCK-HIDA) assesses GBEF and is used to test patients presenting with chronic upper abdominal pain together with a normal upper abdominal ultrasonography.<xref ref-type="bibr" rid="article-19452.r11">[11]</xref>&#x000a0;Tc-99m-labeled HIDA collects in the gallbladder after it is absorbed by the liver and excreted by the biliary system. CCK&#x000a0;is injected to stimulate gallbladder contraction to calculate the GBEF.<xref ref-type="bibr" rid="article-19452.r10">[10]</xref></p>
      </sec>
      <sec id="article-19452.s7" sec-type="Clinical Significance">
        <title>Clinical Significance</title>
        <p>Obesity&#x000a0;blunts the effect of CCK, which means there is insensitivity of vagal afferent neurons to CCK. This reduced expression of CCK accounts for reduced effect on satiety and the fact that most obese people always complain about feeling hungry. Consumption of high-fat diets with diminished expression of the CCK-1 receptor increases the levels of ghrelin in plasma. This increases food intake, and it does this by suppressing the expression of satiety peptide cocaine and amphetamine-regulated transcript (CART) in vagal afferent neurons. CCK is also involved in metabolic regulation and lipid absorption. They link inactivation of the CCK signaling pathway to reduced weight gain. Inactivation increases energy expenditure and lowers energy extraction.<xref ref-type="bibr" rid="article-19452.r9">[9]</xref></p>
        <p>CCK acts via the vasovagal pathway and is activated peripherally via gastric wall distension. They use intragastric balloons in clinical practice to treat weight loss by mimicking this pathway. By distending the stomach it activates the vagal nerve and the nucleus of tractus solitarius and the paraventricular nucleus, leading to a centrally mediated feeling of satiety.<xref ref-type="bibr" rid="article-19452.r12">[12]</xref>&#x000a0;These devices physically reduce food intake by obstructing the outlet, delaying gastric emptying and physically reducing the capacity of the stomach. Pancreatic peptide (PP) secretion is impaired due to decreased gastric emptying which leads to reduced gut wall interactions with nutrients such as fat and protein which&#x000a0;elicit a PP response. PP&#x000a0;secretion is biphasic, and&#x000a0;food and secretion of CCK control the second phase.<xref ref-type="bibr" rid="article-19452.r9">[9]</xref></p>
        <p>CCK plays a minor role in the release of incretin as compared to glucagon-like peptide (GLP-1) from islet cells. Decreased size of islet cells and mass of beta-cells correlates with upregulation of CCK expression and increased sensitivity to CCK for insulin release in obesity. It, therefore, can mediate compensatory mechanisms within the islets of Langerhans.<xref ref-type="bibr" rid="article-19452.r9">[9]</xref> Fat and energy restricted meals stimulate CCK and PP secretion and together with delayed gastric emptying secondary to the intragastric balloon can cause extensive weight loss and improved glucose homeostasis.<xref ref-type="bibr" rid="article-19452.r12">[12]</xref>&#x000a0;Presence of CCK in various regions of the midbrain suggests it plays a role in behavioral processes such and anxiety. They&#x000a0;describe panic disorder as the feeling of unprovoked fear and an overwhelming feeling of anxiety. People with panic disorder or those that experience panic attacks present to the emergency department feeling a sense of impending doom, chest pain, abdominal pain, sometimes even shortness of breath. We know that CCK is expressed in the nucleus of tractus solitarius and area postrema. They associate these areas with nociception and patients with PD are usually sensitive with bodily sensations. Noradrenaline and serotonin (5-HT) containing nuclei found in the brainstem interact with these areas as well implicating then to the pathogenesis of PD.<xref ref-type="bibr" rid="article-19452.r4">[4]</xref></p>
        <p>Cancers of the GI tract including medullary thyroid cancer, small cell lung cancer all express gastrin and CCK-2 receptors. Gastrin and CCK2R/gastrin receptor (GR) play a role in regulating cellular proliferation, loss of cell-cell adhesion, differentiation and morphology and the enhanced motility/invasion of epithelial cells. The activation of the CCK2R/GR via the intracellular signaling pathway can lead to carcinogenesis. These receptors, therefore, play a crucial role in starting the events leading up to preneoplastic lesions and cancer development.<xref ref-type="bibr" rid="article-19452.r13">[13]</xref></p>
      </sec>
      <sec id="article-19452.s8">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=19452&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=19452">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/19452/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=19452">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-19452.s9">
        <title>References</title>
        <ref id="article-19452.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ma</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Dankulich-Nagrudny</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Lowe</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Cholecystokinin: an excitatory modulator of mitral/tufted cells in the mouse olfactory bulb.</article-title>
            <source>PLoS One</source>
            <year>2013</year>
            <volume>8</volume>
            <issue>5</issue>
            <fpage>e64170</fpage>
            <pub-id pub-id-type="pmid">23691163</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19452.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Beinfeld</surname>
                <given-names>MC</given-names>
              </name>
            </person-group>
            <article-title>An introduction to neuronal cholecystokinin.</article-title>
            <source>Peptides</source>
            <year>2001</year>
            <month>Aug</month>
            <volume>22</volume>
            <issue>8</issue>
            <fpage>1197</fpage>
            <page-range>1197-200</page-range>
            <pub-id pub-id-type="pmid">11457511</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19452.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Marino</surname>
                <given-names>CR</given-names>
              </name>
              <name>
                <surname>Leach</surname>
                <given-names>SD</given-names>
              </name>
              <name>
                <surname>Schaefer</surname>
                <given-names>JF</given-names>
              </name>
              <name>
                <surname>Miller</surname>
                <given-names>LJ</given-names>
              </name>
              <name>
                <surname>Gorelick</surname>
                <given-names>FS</given-names>
              </name>
            </person-group>
            <article-title>Characterization of cAMP-dependent protein kinase activation by CCK in rat pancreas.</article-title>
            <source>FEBS Lett</source>
            <year>1993</year>
            <month>Jan</month>
            <day>18</day>
            <volume>316</volume>
            <issue>1</issue>
            <fpage>48</fpage>
            <page-range>48-52</page-range>
            <pub-id pub-id-type="pmid">7678554</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19452.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>van Megen</surname>
                <given-names>HJ</given-names>
              </name>
              <name>
                <surname>den Boer</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Westenberg</surname>
                <given-names>HG</given-names>
              </name>
            </person-group>
            <article-title>On the significance of cholecystokinin receptors in panic disorder.</article-title>
            <source>Prog Neuropsychopharmacol Biol Psychiatry</source>
            <year>1994</year>
            <month>Dec</month>
            <volume>18</volume>
            <issue>8</issue>
            <fpage>1235</fpage>
            <page-range>1235-46</page-range>
            <pub-id pub-id-type="pmid">7863014</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19452.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cao</surname>
                <given-names>SG</given-names>
              </name>
              <name>
                <surname>Wu</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Cai</surname>
                <given-names>ZZ</given-names>
              </name>
            </person-group>
            <article-title>Dose-dependent effect of ghrelin on gastric emptying in rats and the related mechanism of action.</article-title>
            <source>Kaohsiung J Med Sci</source>
            <year>2016</year>
            <month>Mar</month>
            <volume>32</volume>
            <issue>3</issue>
            <fpage>113</fpage>
            <page-range>113-7</page-range>
            <pub-id pub-id-type="pmid">27106000</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19452.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Grider</surname>
                <given-names>JR</given-names>
              </name>
            </person-group>
            <article-title>Role of cholecystokinin in the regulation of gastrointestinal motility.</article-title>
            <source>J Nutr</source>
            <year>1994</year>
            <month>Aug</month>
            <volume>124</volume>
            <issue>8 Suppl</issue>
            <fpage>1334S</fpage>
            <page-range>1334S-1339S</page-range>
            <pub-id pub-id-type="pmid">8064380</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19452.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Burckhardt</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Delco</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Ensinck</surname>
                <given-names>JW</given-names>
              </name>
              <name>
                <surname>Meier</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Bauerfeind</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Aufderhaar</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Ketterer</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Gyr</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Beglinger</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Cholecystokinin is a physiological regulator of gastric acid secretion in man.</article-title>
            <source>Eur J Clin Invest</source>
            <year>1994</year>
            <month>Jun</month>
            <volume>24</volume>
            <issue>6</issue>
            <fpage>370</fpage>
            <page-range>370-6</page-range>
            <pub-id pub-id-type="pmid">7957488</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19452.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Konturek</surname>
                <given-names>JW</given-names>
              </name>
              <name>
                <surname>Konturek</surname>
                <given-names>SJ</given-names>
              </name>
              <name>
                <surname>Kwiecie&#x00144;</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Biela&#x00144;ski</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Pawlik</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Rembiasz</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Domschke</surname>
                <given-names>W</given-names>
              </name>
            </person-group>
            <article-title>Leptin in the control of gastric secretion and gut hormones in humans infected with Helicobacter pylori.</article-title>
            <source>Scand J Gastroenterol</source>
            <year>2001</year>
            <month>Nov</month>
            <volume>36</volume>
            <issue>11</issue>
            <fpage>1148</fpage>
            <page-range>1148-54</page-range>
            <pub-id pub-id-type="pmid">11686213</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19452.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Dockray</surname>
                <given-names>GJ</given-names>
              </name>
            </person-group>
            <article-title>Cholecystokinin.</article-title>
            <source>Curr Opin Endocrinol Diabetes Obes</source>
            <year>2012</year>
            <month>Feb</month>
            <volume>19</volume>
            <issue>1</issue>
            <fpage>8</fpage>
            <page-range>8-12</page-range>
            <pub-id pub-id-type="pmid">22157397</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19452.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Richmond</surname>
                <given-names>BK</given-names>
              </name>
              <name>
                <surname>DiBaise</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Ziessman</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>Utilization of cholecystokinin cholescintigraphy in clinical practice.</article-title>
            <source>J Am Coll Surg</source>
            <year>2013</year>
            <month>Aug</month>
            <volume>217</volume>
            <issue>2</issue>
            <fpage>317</fpage>
            <page-range>317-23</page-range>
            <pub-id pub-id-type="pmid">23731969</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19452.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Watson</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Better</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Kalff</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Nottle</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Scelwyn</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Kelly</surname>
                <given-names>MJ</given-names>
              </name>
            </person-group>
            <article-title>Cholecystokinin (CCK)-HIDA scintigraphy in patients with suspected gall-bladder dysfunction.</article-title>
            <source>Australas Radiol</source>
            <year>1994</year>
            <month>Feb</month>
            <volume>38</volume>
            <issue>1</issue>
            <fpage>30</fpage>
            <page-range>30-3</page-range>
            <pub-id pub-id-type="pmid">8147796</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19452.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mathus-Vliegen</surname>
                <given-names>EM</given-names>
              </name>
              <name>
                <surname>de Groot</surname>
                <given-names>GH</given-names>
              </name>
            </person-group>
            <article-title>Fasting and meal-induced CCK and PP secretion following intragastric balloon treatment for obesity.</article-title>
            <source>Obes Surg</source>
            <year>2013</year>
            <month>May</month>
            <volume>23</volume>
            <issue>5</issue>
            <fpage>622</fpage>
            <page-range>622-33</page-range>
            <pub-id pub-id-type="pmid">23224567</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19452.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rai</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Chandra</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Tewari</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Kumar</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Shukla</surname>
                <given-names>HS</given-names>
              </name>
            </person-group>
            <article-title>Cholecystokinin and gastrin receptors targeting in gastrointestinal cancer.</article-title>
            <source>Surg Oncol</source>
            <year>2012</year>
            <month>Dec</month>
            <volume>21</volume>
            <issue>4</issue>
            <fpage>281</fpage>
            <page-range>281-92</page-range>
            <pub-id pub-id-type="pmid">22801592</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
